Paper Details

  1. Home
  2. Paper Details

The D1/D5 Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson's Disease: A Feasibility Study.

Author: ArnoldAmy C, De JesusSol, DelnomdedieuMarielle, DuvvuriSridhar, EslingerPaul J, Fernandez-MendozaJulio, GrayDavid L, HarringtonWilliam, HuangXuemei, KongLan, LewisMechelle M, MahoneySusan E, MailmanRichard B, MillerAmanda J, SnyderBethany, SunDongxiao, Van ScoyLauren Jodi, WangXi

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

A two-week, randomized, double-blind, crossover phase Ib study was conducted to determine the feasibility and safety of the selective D1/D5 dopamine partial agonist PF 06412562 in patients with advanced-to-end-stage Parkinson's disease (advPD). Six patients were randomized to receive either standard-of-care (SoC) carbidopa/levodopa or PF 06412562. The study found that PF 06412562 was tolerated in advPD patients and provides feasibility for future safety and efficacy studies in this population with unmet needs.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Current drug treatments have little efficacy in advanced-to-end-stage Parkinson's disease (advPD), yet there are no reports of interventional trials in advPD. D1 dopamine agonists have the potential to provide benefit. OBJECTIVE: To determine the feasibility and safety of the selective ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/32986682

データ提供：米国国立医学図書館（NLM）

A New Hope for Advanced Parkinson's Disease: Exploring the Potential of PF-06412562

This feasibility study investigates the potential of PF-06412562, a selective D1/D5 dopamine partial agonist, as a treatment option for patients with advanced-stage Parkinson's disease (advPD). The researchers conducted a two-week, randomized, double-blind crossover study comparing PF-06412562 with standard-of-care carbidopa/levodopa in a small group of advPD patients. This study uses a feasibility approach to assess the safety and tolerability of PF-06412562 in advPD patients.

PF-06412562: A Promising Candidate for Advanced Parkinson's Disease

The study demonstrates that PF-06412562 was generally well-tolerated in advPD patients, suggesting its potential as a safe and effective treatment option. The study provides preliminary evidence supporting the feasibility of further clinical trials to evaluate the efficacy of PF-06412562 in this population. This research offers hope for patients with advPD, who currently have limited treatment options.

Advanced Parkinson's Disease: Seeking New Solutions

This study highlights the urgent need for effective treatment options for patients with advPD, a condition characterized by significant disability and limited therapeutic choices. It underscores the importance of ongoing research and development of new therapies to address the specific needs of this patient population. This research encourages a renewed focus on finding innovative solutions for advPD, recognizing the immense unmet need for effective treatments.

Dr. Camel's Conclusion

This study, like a lone camel seeking an oasis in the vast desert of advanced Parkinson's disease, offers a glimmer of hope. It suggests that PF-06412562 may be a promising new treatment option for this challenging condition, potentially leading to improved quality of life for affected patients.

Date :
  1. Date Completed 2021-09-15
  2. Date Revised 2023-11-08
Further Info :

Pubmed ID

32986682

DOI: Digital Object Identifier

NIHMS1753238

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.